Daiichi Sankyo Co Ltd at JPMorgan Healthcare Conference Transcript
All right. Good afternoon, everyone, and welcome to the conference. My name is Naomi Kumagai, Japan pharma analyst at JPMorgan. It's my great pleasure to introduce Mr. Manabe, President and CEO of Daiichi Sankyo. After the presentation, the breakout will be in Yorkshire. Over to you.
Good afternoon. Thank you all for being here today. I would like also thank to JPMorgan for giving this opportunity. This is my first presentation, this JPMorgan Health Care Conference. Let me introduce myself briefly.
I started my career at Daiichi Sankyo as a toxicologist in 1978. I spent the first 30 years at Daiichi Sankyo in R&D. During this time, I was directly involved in developing several global projects, including pravastatin, olmesartan and edoxaban. Since moving to the headquarter, joining to the senior Daiichi Sankyo team, I have been responsible for a wide range of functions,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |